Asthma patients may soon treat themselves with first-ever digital maintenance inhaler.
Patients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.
EpiPens have been in short supply, but stakeholders are trying to fill in the access gap.
While some are concerned that President Trump’s proposed “favored nations” policy would harm pharma makers, one analyst is not as concerned.
FDA warns opioid repackers for "significant violations."
FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.
The validity of a new large study linking anticholinergic drugs to the risk of dementia has stirred up controversy.
FDA recalls insulin pumps due to cybersecurity miscommunication.
A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.
A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.